Regeneron Salvages What It Can: The Acquisition of 23andMe Opens a New Chapter for Both Parties
Just a few years ago, 23andMe was synonymous with a pioneer in the field of genetic testing for consumers. Its IPO took place in 2021, and at the peak of its performance, the company boasted a total value of around $6 billion, but since then the dream has gradually crumbled. The troubled period began with a massive leak of sensitive data of its customers, later the situation worsened financially, and bankruptcy is currently underway, in which Regeneron is involved. Will it help?